

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES



Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



chain nodes :

13 14 23 24 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20

chain bonds :

10-13 13-14 14-15 23-24 24-25 25-26 25-27

ring bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

1-10 6-7 7-8 8-9 9-10 10-13 13-14 14-15 23-24 24-25 25-26 25-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

isolated ring systems :

containing 1 : 15 :

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 13:CLASS
14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS

=>


Uploading 09975741.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:25:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 720 TO 1640

PROJECTED ANSWERS: 22 TO 418

L2 11 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 15:26:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1089 TO ITERATE

100.0% PROCESSED 1089 ITERATIONS

171 ANSWERS

SEARCH TIME: 00.00.01

L3 171 SEA SSS FUL L1

=> s l3

L4 5 L3

=> d l4 1-5 bib,ab,hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:633683 CAPLUS
 DN 139:185673
 TI Preparation and compositions of polymorphic forms of bicyclic antidiabetic agents
 IN Srisilla, Raju; Potlapally, Rajender Kumar; Mamillapalli, Ramabhadra
 Sarma; Gaddam, Om Reddy
 PA Reddy's Laboratories Limited, India
 SO PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

not prior *Common* *g.w.*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066612	A1	20030814	WO 2003-IB408	20030207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI IN 2002-MA95 A 20020207

AB This invention relates to novel polymorphic/pseudopolymorphic forms and compns. of arginine salt of 3-[4-[2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, preferably, L-arginine salt of (2S)-3-[4-[2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid. The polymorphic forms of the present invention are more active, as antidiabetic and hypolipidemic agent, than the 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.

IT 305827-56-9P

RL: PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(prepn. and compns. of polymorphic forms of arginine salt of benzothiazine antidiabetic/hypolipidemic agent)

RN 305827-56-9 CAPLUS


CN L-Arginine, mono[(.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




IT 223607-27-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. and compns. of polymorphic forms of arginine salt of
 benzothiazine antidiabetic/hypolipidemic agent)

RN 223607-27-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:242313 CAPLUS

DN 138:255240

TI An improved process for the preparation of bicyclic antidiabetic compounds, specifically (S)-3-[4-[2-(3,4-dihydro-2H-benzo[b][1,4]thiazin-4-yl)ethoxy]phenyl]-2-alkoxypropanoic acids and their oxazin-4-yl analogs, using optimized bases and solvents for etherification

IN Batchu, Chandrasekhar; Addanki, Sivaramaprasad; Mamillapalli, Ramabhadrasarma; Gaddam, Omreddy

PA Reddy's Laboratories Ltd., India

SO PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024944	A1	20030327	WO 2002-IB3875	20020920
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRAI IN 2001-MA778 A 20010920

OS CASREACT 138:255240; MARPAT 138:255240

AB The invention relates to an improved process for the prepn. of antidiabetic compds. I [wherein: R1 = (C1-C6)alkyl; X = S or O atom]. The method involves (1) etherification of phenol derivs. II [R1, R2 = (C1-C6)alkyl] with mesylates III in the presence of a base and solvent at 10-150.degree. over 2-30 h to give esters IV; (2) hydrolysis of IV by a base and a solvent at 10-40.degree. over 20 min to 12 h; and (3) isolation of I by conventional methods. In particular, the base in both steps is selected from Na2CO3, K2CO3, NaOH, or KOH, and the solvent is selected from toluene, xylene, MeOH, EtOH, n-PrOH, iso-PrOH, or their mixts. I are known antidiabetic agents, with preps. previously described in US 6,265,401 and WO 00/66572. Disadvantages of these prior art methods include moisture-sensitive reactions, use of column chromatog., low yields, long cycle times, impure products, and an inconvenient solvent (DMF). The new method is simple, safe, scalable to com. prodn., and uses inexpensive chems. The new solvents give improved yields and drastically reduced cycle times, making the process com. viable. For instance, etherification of (-)-II [R1 = R2 = Et] with III [X = S] using K2CO3 in refluxing toluene for 4-5 h with azeotropic removal of H2O gave 92% (-)-IV [R1 = R2 = Et; X = S] of 97% purity. The latter ester in MeOH was hydrolyzed by 10% NaOH soln. at <20.degree. and then at 25-35.degree., followed by extn. with PhMe and acidification with 25% H2SO4, to give 82% (-)-I [R1 = R2 = Et; X = S], also of 97% purity. Nearly identical results were obtained for the case of R1 = Et, R2 = iso-Pr, X = S.


IT **305827-41-2P**, (S)-(-)-Ethyl 3-[4-[2-(3,4-dihydro-2H-benzo[b][1,4]thiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoate
503056-17-5P, (S)-(-)-Isopropyl 3-[4-[2-(3,4-dihydro-2H-benzo[b][1,4]thiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoate

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; improved prepn. of bicyclic antidiabetic compds. by etherification of phenol and mesylate derivs.)

RN 305827-41-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, ethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 503056-17-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, 1-methylethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT **223607-27-0P**, (S)-(-)-3-[4-[2-(3,4-Dihydro-2H-benzo[b][1,4]thiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(product; improved prepn. of bicyclic antidiabetic compds. by etherification of phenol and mesylate derivs.)

RN 223607-27-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:293636 CAPLUS
 DN 136:319405
 TI Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
 IN Gaddam, Om Reddy; Batchu, Chandrasekhar; Mamillapalli, Ramabhadra Sarma; Addanki, Siva Rama Prasad
 PA Reddy's Research Foundation, India
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

*Appl.
PCT.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030914	A1	20020418	WO 2001-IN175	20011010
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002012672	A5	20020422	AU 2002-12672	20011010
	US 2002142993	A1	20021003	US 2001-975741	20011010
PRAI	IN 2000-MA863	A	20001012		
	US 2001-266996P	P	20010205		
	WO 2001-IN175	W	20011010		

OS MARPAT 136:319405

AB The present invention relates to pharmaceutically acceptable salts of compd. of the general formula (I), their derivs., their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. contg. them. wherein R1 represents hydrogen, halogen atom such as fluorine, chlorine, bromine or iodine; hydroxy, nitro, cyano or lower alkyl group; R2 represents hydrogen, lower alkyl or oxo group; X represents a heteroatom selected from oxygen or sulfur; R3 represents hydrogen or lower alkyl group; n is an integer ranging from 1-4; M represents a counter ion or a moiety which forms a pharmaceutically acceptable salt; p is an integer ranging from 1 to 2. Examples are provided showing effectiveness of such compds. in inhibiting HMG CoA reductase activity, and in lowering plasma triglyceride and cholesterol levels.

IT 412316-40-6P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(salts of benzothiazines and benzoxazines for treatment of various diseases such as atherosclerosis and diabetes)


RN 412316-40-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, (.alpha.S)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0
CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (-).



*Electro
Species*

CM 2

CRN 657-24-9
CMF C4 H11 N5



IT 412316-39-3P 412316-41-7P 412316-42-8P
412316-43-9P 412316-44-0P 412316-45-1P
412316-47-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(salts of benzothiazines and benzoxazines for treatment of various diseases such as atherosclerosis and diabetes)


RN 412316-39-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, (.alpha.S)-, compd. with (.beta.S)-.beta.-aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0
CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 20989-17-7
 CMF C8 H11 N O

Absolute stereochemistry. Rotation (+).




RN 412316-41-7 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with N-cyclohexylcyclohexanamine
 (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 223607-27-0
 CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 101-83-7
CMF C12 H23 N


RN 412316-42-8 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.S)-, compd. with (.alpha.R)-.alpha.-
methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0
CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2


CRN 3886-69-9
CMF C8 H11 N

Absolute stereochemistry.



RN 412316-43-9 CAPLUS


CN L-Lysine, mono[(.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)



CM 2

CRN 79-17-4


CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2



RN 412316-45-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-
 propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 77-86-1

CMF C4 H11 N O3



RN 412316-47-3 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, (.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 223607-27-0

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



IT 412316-48-4 412316-49-5 412316-50-8
 412316-51-9 412316-52-0 412316-53-1
 412316-54-2 412316-55-3 412316-56-4
 412316-57-5 412316-58-6 412316-59-7
 412316-60-0 412316-61-1 412316-62-2
 412316-63-3 412316-64-4 412316-65-5
 412316-66-6 412316-67-7 412316-68-8
 412316-69-9 412316-70-2 412316-71-3
 412316-72-4 412316-73-5 412316-74-6
 412316-75-7 412316-76-8 412316-77-9
 412316-78-0 412316-79-1 412316-80-4
 412316-81-5 412316-82-6 412316-83-7
 412316-84-8 412316-85-9 412317-72-7
 412317-73-8 412317-74-9 412317-76-1
 412915-55-0 412915-57-2 412915-58-3
 412915-59-4 412915-60-7 412915-63-0
 412915-66-3 412915-68-5 412915-69-6
 412915-70-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (salts of benzothiazines and benzoxazines for treatment of various
 diseases such as atherosclerosis and diabetes)


RN 412316-48-4 CAPLUS

CN L-Lysine, mono[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-
 ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6

CMF C21 H25 N O5




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 412316-49-5 CAPLUS


CN L-Lysine, mono[(.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 412316-50-8 CAPLUS

CN L-Lysine, mono[4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7

CMF C21 H25 N O4 S




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 412316-51-9 CAPLUS


CN L-Lysine, mono[(.alpha.R)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (+).




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 412316-52-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA
 INDEX NAME)

CM 1

CRN 223607-15-6


CMF C21 H25 N O5



CM 2

CRN 101-83-7

CMF C12 H23 N



RN 412316-53-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with N-cyclohexylcyclohexanamine
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 101-83-7

CMF C12 H23 N




RN 412316-54-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 223607-24-7


CMF C21 H25 N O4 S



CM 2

CRN 101-83-7

CMF C12 H23 N



RN 412316-55-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)-, compd. with N-cyclohexylcyclohexanamine
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 101-83-7

CMF C12 H23 N




RN 412316-56-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1


CRN 223607-15-6

CMF C21 H25 N O5



CM 2

CRN 657-24-9
 CMF C4 H11 N5




RN 412316-57-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with N,N-dimethylimidodicarbonimidic
 diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8
 CMF C21 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 657-24-9

CMF C4 H11 N5




RN 412316-58-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7


CMF C21 H25 N O4 S



CM 2

CRN 657-24-9

CMF C4 H11 N5



RN 412316-59-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, (.alpha.R)-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 657-24-9

CMF C4 H11 N5




RN 412316-60-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA
 INDEX NAME)

CM 1

CRN 223607-24-7


CMF C21 H25 N O4 S



CM 2

CRN 79-17-4

CMF C H6 N4



RN 412316-61-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with hydrazinecarboximidamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79-17-4

CMF C H6 N4



RN 412316-62-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)-, compd. with hydrazinecarboximidamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4

CMF C H6 N4




RN 412316-63-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with hydrazinecarboximidamide (1:1) (9CI) (CA
 INDEX NAME)

CM 1

CRN 223607-15-6


CMF C21 H25 N O5



CM 2

CRN 79-17-4

CMF C H6 N4



RN 412316-64-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with hydrazinecarboximidamide (1:1)


(9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79-17-4

CMF C H6 N4




RN 412316-65-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with (.alpha.R)-.alpha.-methylbenzenemethanamine
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6

CMF C21 H25 N O5




CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry.



RN 412316-66-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with (.alpha.R)-.alpha.-
 methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry.




RN 412316-67-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with (.alpha.R)-.alpha.-methylbenzenemethanamine
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7

CMF C21 H25 N O4 S




CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry.



RN 412316-68-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)-, compd. with (.alpha.R)-.alpha.-
 methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (+).




CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry.




RN 412316-69-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with hydrazinecarboximidamide (1:1), monoformate
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7


CMF C21 H25 N O4 S



CM 2

CRN 79-17-4


CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2



RN 412316-70-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, (.alpha.R)-, compd. with hydrazinecarboximidamide (1:1), monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4


CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2




RN 412316-71-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with hydrazinecarboximidamide (1:1), monoformate
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6


CMF C21 H25 N O5



CM 2

CRN 79-17-4


CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2



RN 412316-72-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, (.alpha.S)-, compd. with hydrazinecarboximidamide (1:1), monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 79-17-4

CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2




RN 412316-73-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7


CMF C21 H25 N O4 S



CM 2

CRN 77-86-1

CMF C4 H11 N O3



RN 412316-74-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-
 propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S


Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-86-1

CMF C4 H11 N O3




RN 412316-75-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6


CMF C21 H25 N O5



CM 2

CRN 77-86-1

CMF C4 H11 N O3



RN 412316-76-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-
 propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5


Absolute stereochemistry. Rotation (-).



CM 2

CRN 77-86-1

CMF C4 H11 N O3




RN 412316-77-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(octylamino)-, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7

CMF C21 H25 N O4 S




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry.



RN 412316-78-0 CAPLUS


CN D-Glucitol, 1-deoxy-1-(octylamino)-, (.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 223607-27-0

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry.



RN 412316-79-1 CAPLUS


CN D-Glucitol, 1-deoxy-1-(octylamino)-, (.alpha.R)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (+).




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry.




RN 412316-80-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(octylamino)-, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6

CMF C21 H25 N O5




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry.



RN 412316-81-5 CAPLUS


CN D-Glucitol, 1-deoxy-1-(octylamino)-, (.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry.




RN 412316-82-6 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6

CMF C21 H25 N O5




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



RN 412316-83-7 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, (.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 412316-84-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 223607-24-7

CMF C21 H25 N O4 S




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



RN 412316-85-9 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, (.alpha.R)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (+).




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 412317-72-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with (.beta.S)-.beta.-aminobenzeneethanol (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-24-7

CMF C21 H25 N O4 S




CM 2

CRN 20989-17-7

CMF C8 H11 N O

Absolute stereochemistry. Rotation (+).



RN 412317-73-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)-, compd. with (.beta.S)-.beta.-
 aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-25-8

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (+).




CM 2

CRN 20989-17-7

CMF C8 H11 N O

Absolute stereochemistry. Rotation (+).




RN 412317-74-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, compd. with (.beta.S)-.beta.-aminobenzeneethanol (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6

CMF C21 H25 N O5




CM 2

CRN 20989-17-7

CMF C8 H11 N O

Absolute stereochemistry. Rotation (+).



RN 412317-76-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.S)-, compd. with (.beta.S)-.beta.-
 aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 20989-17-7

CMF C8 H11 N O

Absolute stereochemistry. Rotation (+).



RN 412915-55-0 CAPLUS


CN L-Lysine, mono[rel-(+)-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 412915-57-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, rel-(+)-, compd. with N-cyclohexylcyclohexanamine (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7

CMF C21 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 101-83-7

CMF C12 H23 N




RN 412915-58-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, rel-(+)-, compd. with N,N-dimethylimidodicarbonimidic
diamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 223607-16-7
CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2


CRN 657-24-9
CMF C4 H11 N5

RN 412915-59-4 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, rel-(+)-, compd. with hydrazinecarboximidamide (1:1)
 (9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7
CMF C21 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4

CMF C H6 N4



RN 412915-60-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, rel-(+)-, compd. with (.alpha.R)-.alpha.-
 methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 3886-69-9

CMF C8 H11 N

Absolute stereochemistry.



RN 412915-63-0 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)-, formate, compd. with
 hydrazinecarboximidamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7

CMF C21 H25 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 79-17-4


CMF C H6 N4



CM 3

CRN 64-18-6

CMF C H2 O2




RN 412915-66-3 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, rel-(+)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-
 propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 223607-16-7
 CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-86-1
 CMF C4 H11 N O3




RN 412915-68-5 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(octylamino)-, rel-(+)-4-[2-(2,3-dihydro-4H-1,4-
 benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA
 INDEX NAME)

CM 1

CRN 223607-16-7
 CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 23323-37-7

CMF C14 H31 N O5

Absolute stereochemistry.



RN 412915-69-6 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, rel-(+)-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



RN 412915-70-9 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, rel-(+)-, compd. with (.beta.S)-.beta.-
 aminobenzeneethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 223607-16-7

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 20989-17-7

CMF C8 H11 N O

Absolute stereochemistry. Rotation (+).



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:790490 CAPLUS

DN 133:350232

TI Substituted .beta.-aryl-.alpha.-oxy-substituted propionic acids, particularly benzoxazines and benzothiazines, process for their preparation, and their use as antiobesity and hypocholesterolemic agents

IN Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Ashok, Channaveerappa Bajji; Kalchar, Shivaramayya; Gurram, Ranga Madhavan; Rajagopalan, Ramanujam; Ranjan, Chakrabarti

PA Reddy's Research Foundation, India

SO PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

not prior

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066572	A1	20001109	WO 2000-IB501	20000425
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1175412	A1	20020130	EP 2000-919081	20000425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE	200100540	A	20021216	EE 2001-540	20000425
JP	2002543194	T2	20021217	JP 2000-615602	20000425
HR	2001000785	A1	20030228	HR 2001-785	20011024
NO	2001005259	A	20011115	NO 2001-5259	20011026
BG	106146	A	20020531	BG 2001-106146	20011126
PRAI	IN 1999-MA484	A	19990428		
	WO 2000-IB501	W	20000425		


OS MARPAT 133:350232

AB Title compds. I [R1-R6 (when bound to C) = H, halo, OH, NO₂, cyano, CHO, (substituted) alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, amino, acylamino, aralkoxycarbonyl, alkylthio, etc.; R5 and/or R6 (on C) may also be oxo; R7 = H, OH, alkoxy, halo, alkyl, (substituted) aralkyl; R8 = R7, acyl; or R7R8 = pi bond; R9 = H, (substituted) alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxycarbonyl, alkylaminocarbonyl, acyl, heterocyclyl, heteroaryl, etc.; R10 = H, (substituted) alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl; X = S, O, NR11; R11 = H, (substituted) alky, aryl, acyl, etc.; Y = O, NR12; R12 = H, alkyl, aryl, hydroxyalkyl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl; R10R12 may form 5- to 6-membered N-contg. heterocyclyl; n = 1-4; m = 0, 1; Ar = (substituted) single or fused arom. or heterocyclic divalent group]. The compds. are agonists at PPAR.alpha. and/or PPAR.gamma., and optionally inhibit HMG-CoA reductase. They are thus useful in a variety of pharmaceutical roles, particularly as antiobesity and hypocholesterolemic agents. Examples include 77 syntheses and 5 precursor preps., plus several bioassays. For instance, title compd. II was prepd. by etherification of the corresponding phenol deriv. and benzothiazinylethyl mesylate ester (70% yield). At doses of 1-10 mg/kg orally in mice, selected compds. I reduced plasma triglyceride levels by 23-74%, blood

glucose by 45-53%, and total cholesterol levels by 42-57%.


IT **223607-15-6P 223607-17-8P**, (S)-(-)-2-Ethoxy-3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]propanoic acid
223607-24-7P 223607-27-0P, (S)-(-)-2-Ethoxy-3-[4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]propanoic acid
305827-41-2P, (S)-(-)-Ethyl 2-ethoxy-3-[4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]propanoate **305827-45-6P**, (R)-(+)-Ethyl 2-ethoxy-3-[4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]propanoate **305827-61-6P**, (S)-(-)-Ethyl 2-ethoxy-3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]propanoate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of benzoxazines and benzothiazines as antiobesity and hypocholesterolemic agents)

RN 223607-15-6 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy- (9CI) (CA INDEX NAME)




RN 223607-17-8 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 223607-24-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-27-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 305827-41-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, ethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 305827-45-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, ethyl ester, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 305827-61-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, ethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 223606-56-2P 223606-57-3P 223606-58-4P
 223606-64-2P 223606-65-3P 223606-66-4P
 223606-67-5P 223606-68-6P 223606-70-0P
 223606-71-1P 223606-72-2P 223606-73-3P
 223606-75-5P 223606-76-6P 223606-78-8P
 223606-89-1P 223606-92-6P 223606-95-9P
 223606-97-1P 223606-99-3P 223607-02-1P
 223607-03-2P 223607-04-3P 223607-06-5P
 223607-07-6P 223607-08-7P 223607-16-7P
 223607-25-8P, (R)-(+)-2-Ethoxy-3-[4-[2-(2,3-dihydro-4H-1,4-
 benzothiazin-4-yl)ethoxy]phenyl]propanoic acid 223607-51-0P
 223607-52-1P 223607-54-3P 223607-55-4P
 223607-56-5P 223607-57-6P 223607-58-7P
 223607-59-8P 223607-67-8P 223607-69-0P
 223607-71-4P 223607-73-6P 223607-74-7P


223607-75-8P 223607-76-9P 223607-77-0P
 223607-78-1P 223607-80-5P 223607-82-7P
 223607-83-8P 223607-84-9P 223607-86-1P
 223607-87-2P 223607-88-3P 223607-89-4P
 223607-90-7P 223607-91-8P 223607-92-9P
 223607-93-0P 223607-94-1P 223607-95-2P
 223607-96-3P 223607-97-4P 223607-99-6P
 223608-00-2P 223608-01-3P 223608-02-4P
 223608-03-5P 223608-04-6P 223608-05-7P
 223608-06-8P 223608-07-9P 223608-08-0P
 223608-09-1P 223608-18-2P 223608-19-3P
 223608-20-6P 223608-21-7P 223608-22-8P
 223608-24-0P 223608-25-1P 223608-26-2P
 223608-27-3P 223608-28-4P 305827-50-3P,
 3-[4-[2-(2,3-Dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-
 ethoxypropanoic acid magnesium salt 305827-52-5P,
 (S)-(-)-3-[4-[2-(2,3-Dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-
 ethoxypropanoic acid sodium salt 305827-54-7P,
 (S)-(-)-3-[4-[2-(2,3-Dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-
 ethoxypropanoic acid magnesium salt 305827-56-9P,
 (S)-(-)-3-[4-[2-(2,3-Dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-
 ethoxypropanoic acid arginine salt 305827-58-1P,
 3-[4-[2-(2,3-Dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-
 ethoxypropanoic acid arginine salt 305827-65-0P
 305827-67-2P, (S)-(-)-3-[4-[2-(2,3-Dihydro-4H-1,4-benzoxazin-4-
 yl)ethoxy]phenyl]-2-ethoxypropanoic acid arginine salt
 305827-89-8P, (+)-Ethyl 3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-
 yl)ethoxy]phenyl]-2-hydroxypropanoate 305827-91-2P, (-)-Ethyl
 3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-
 hydroxypropanoate 305827-92-3P, (+)-Ethyl 3-[4-[2-(2,3-dihydro-
 4H-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-hydroxypropanoate
 305827-93-4P, (-)-Ethyl 3-[4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-
 yl)ethoxy]phenyl]-2-hydroxypropanoate 305827-94-5P, (+)-Ethyl
 3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-
 benzyloxypropanoate 305827-96-7P, (-)-Ethyl 3-[4-[2-(2,3-dihydro-
 4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-benzyloxypropanoate
 305827-98-9P, (+)-Ethyl 3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-
 yl)ethoxy]phenyl]-2-butoxypropanoate 305828-00-6P, (-)-Ethyl
 3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-
 butoxypropanoate 305828-02-8P, (+)-Ethyl 3-[4-[2-(2,3-dihydro-4H-
 1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-hexyloxypropanoate
 305828-04-0P, (-)-Ethyl 3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-
 yl)ethoxy]phenyl]-2-hexyloxypropanoate 305828-20-0P,
 (+)-2-Methyl-3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-
 ethoxypropanoic acid 305828-22-2P, (-)-2-Methyl-3-[4-[2-(2,3-
 dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid
 305828-24-4P, (+)-2-(2-Fluorobenzyl)-3-[4-[2-(2,3-dihydro-4H-1,4-
 benzoxazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 305828-26-6P
 , (-)-2-(2-Fluorobenzyl)-3-[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-
 yl)ethoxy]phenyl]-2-ethoxypropanoic acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of benzoxazines and benzothiazines as
 antiobesity and hypocholesterolemic agents)
 RN 223606-56-2 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-57-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-58-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223606-64-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-65-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-66-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223606-67-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-68-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, methyl ester, rel-(+)- (9CI) (CA INDEX
NAME)


Rotation (+).



RN 223606-70-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, methyl ester, rel-(-)- (9CI) (CA INDEX
NAME)


Rotation (-).




RN 223606-71-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 223606-72-2 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, methyl ester, rel-(+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-73-3 CAPLUS


CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, methyl ester, rel-(-)-(9CI) (CA INDEX NAME)

Rotation (-).



RN 223606-75-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-76-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-78-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 223606-89-1 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-92-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-95-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-97-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-99-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(hexyloxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223607-02-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223607-03-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-04-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-06-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223607-07-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-08-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 223607-16-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 223607-25-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 223607-51-0 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 223607-52-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 223607-54-3 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-55-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-56-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-57-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-58-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-59-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-67-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 223607-69-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-71-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-73-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 223607-74-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-75-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-76-9 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 223607-77-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-78-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-80-5 CAPLUS


CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 223607-82-7 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-83-8 CAPLUS


CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-84-9 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(hexyloxy)- (9CI) (CA INDEX NAME)



RN 223607-86-1 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-87-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-88-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223607-89-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-90-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-91-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223607-92-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-93-0 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-94-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223607-95-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-96-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX
NAME)

Rotation (-).



RN 223607-97-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-methyl-.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223607-99-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-methyl-.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-00-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-methyl-.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223608-01-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223608-02-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-03-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223608-04-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223608-05-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-06-8 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-).




RN 223608-07-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 223608-08-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, 4-nitrophenyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-09-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, 4-nitrophenyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 223608-18-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-19-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, sodium salt (9CI) (CA INDEX NAME)



RN 223608-20-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-.alpha.-methyl-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-21-7 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 223608-22-8 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-24-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(phenylmethoxy)-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-25-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-26-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-27-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-28-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, sodium salt (9CI) (CA INDEX NAME)



RN 305827-50-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, magnesium salt (9CI) (CA INDEX NAME)



RN 305827-52-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, sodium salt, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 305827-54-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, magnesium salt, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● 1/2 Mg

RN 305827-56-9 CAPLUS


CN L-Arginine, mono[(.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-27-0

CMF C21 H25 N O4 S

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 305827-58-1 CAPLUS

CN L-Arginine, mono[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-15-6

CMF C21 H25 N O5




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 305827-65-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-

.alpha.-ethoxy-, magnesium salt, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● 1/2 Mg

RN 305827-67-2 CAPLUS


CN L-Arginine, mono[(.alpha.S)-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxybenzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 223607-17-8

CMF C21 H25 N O5

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 305827-89-8 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-hydroxy-, ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305827-91-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-hydroxy-, ethyl ester, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 305827-92-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-hydroxy-, ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305827-93-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-hydroxy-, ethyl ester, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 305827-94-5 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-(phenylmethoxy)-, ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305827-96-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(phenylmethoxy)-, ethyl ester, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 305827-98-9 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305828-00-6 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, ethyl ester, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 305828-02-8 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(hexyloxy)-, ethyl ester, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305828-04-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, ethyl ester, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 305828-20-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305828-22-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 305828-24-4 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 305828-26-6 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:286013 CAPLUS
 DN 130:311806
 TI Preparation of benzoxazines and benzothiazines as antiobesity and
 hypocholesterolemic agents.
 IN Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Bajji, Ashok Channaveerappa;
 Kalchar, Shivaramayya; Ramanujam, Rajagopalan; Chakrabarti, Ranjan
 PA Reddy's Research Foundation, India; Reddy-Cheminor, Inc.
 SO PCT Int. Appl., 121 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920614	A1	19990429	WO 1998-US22570	19981026
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6265401	B1	20010724	US 1998-85292	19980527
	CA 2307068	AA	19990429	CA 1998-2307068	19981026
	AU 9911206	A1	19990510	AU 1999-11206	19981026
	AU 752059	B2	20020905		
	BR 9812770	A	20001212	BR 1998-12770	19981026
	EP 1082313	A1	20010314	EP 1998-953970	19981026
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002507543	T2	20020312	JP 2000-516956	19981026
	NZ 504106	A	20030228	NZ 1998-504106	19981026
	ZA 9809781	A	19990825	ZA 1998-9781	19981027
	NO 2000002114	A	20000626	NO 2000-2114	20000426
	US 2001051619	A1	20011213	US 2001-816584	20010323
	US 2002082258	A1	20020627	US 2001-820485	20010329
PRAI	IN 1997-MA2417	A	19971027		
	US 1998-85292	A2	19980527		
	WO 1998-US22570	W	19981026		
OS	MARPAT 130:311806				
AB	Title compds. I; R1-R6 = H, halo, OH, NO ₂ , cyano, CHO, (substituted) alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, amino, acylamino, aralkoxycarbonyl, alkylthio, etc.; R7 = H, OH, alkoxy, halo, alkyl, (substituted) aralkyl, bond; R8 = R7, acyl; R9 = H, (substituted) alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, aryloxyalkyl, alkylaminocarbonyl, acyl, heterocyclyl, heteroaryl, etc.; R10 = H, (substituted) alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl; Y = O, NR ₁₂ ; R12 = H, alkyl, aryl, hydroxyalkyl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl; R10R12 = 5-6 membered (hetero)cyclyl; n = 1-4; m = 0, 1; Ar = (substituted) divalent. Thus, 3-[6-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]naphthyl]-2-ethoxypropanoic acid Na salt (prepn. given) at 1 mg/kg orally in rats reduced plasma triglyceride and total cholesterol levels by 50% and 42%, resp.				
IT	223606-56-2P 223606-57-3P 223606-58-4P 223606-64-2P 223606-65-3P 223606-66-4P				


223606-67-5P 223606-68-6P 223606-70-0P
 223606-71-1P 223606-72-2P 223606-73-3P
 223606-75-5P 223606-76-6P 223606-78-8P
 223606-89-1P 223606-92-6P 223606-95-9P
 223606-97-1P 223606-99-3P 223607-02-1P
 223607-03-2P 223607-04-3P 223607-06-5P
 223607-07-6P 223607-08-7P 223607-15-6P
 223607-16-7P 223607-17-8P 223607-24-7P
 223607-25-8P 223607-27-0P 223607-51-0P
 223607-52-1P 223607-54-3P 223607-55-4P
 223607-56-5P 223607-57-6P 223607-58-7P
 223607-59-8P 223607-67-8P 223607-69-0P
 223607-71-4P 223607-73-6P 223607-74-7P
 223607-75-8P 223607-76-9P 223607-77-0P
 223607-78-1P 223607-80-5P 223607-82-7P
 223607-83-8P 223607-84-9P 223607-86-1P
 223607-87-2P 223607-88-3P 223607-89-4P
 223607-90-7P 223607-91-8P 223607-92-9P
 223607-93-0P 223607-94-1P 223607-95-2P
 223607-96-3P 223607-97-4P 223607-99-6P
 223608-00-2P 223608-01-3P 223608-02-4P
 223608-03-5P 223608-04-6P 223608-05-7P
 223608-06-8P 223608-07-9P 223608-08-0P
 223608-09-1P 223608-18-2P 223608-19-3P
 223608-20-6P 223608-21-7P 223608-22-8P
 223608-24-0P 223608-25-1P 223608-26-2P
 223608-27-3P 223608-28-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzoxazines and benzothiazines as antiobesity and hypocholesterolemic agents)

RN 223606-56-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-57-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-58-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223606-64-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-65-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-66-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223606-67-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-68-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl-, methyl ester, rel-(+)- (9CI) (CA INDEX
NAME)


Rotation (+).



RN 223606-70-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-.alpha.-methyl-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-).




RN 223606-71-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 223606-72-2 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, methyl ester, rel-(+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-73-3 CAPLUS


CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223606-75-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223606-76-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223606-78-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 223606-89-1 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-92-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-95-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-97-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 223606-99-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223607-02-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223607-03-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-04-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-06-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223607-07-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-08-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-15-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-16-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 223607-17-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 223607-24-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-25-8 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
 .alpha.-ethoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 223607-27-0 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 223607-51-0 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 223607-52-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 223607-54-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-55-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-56-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-57-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy- (9CI) (CA INDEX NAME)



RN 223607-58-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-59-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-ethoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-67-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 223607-69-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-71-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-73-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-hydroxy- (9CI) (CA INDEX NAME)



RN 223607-74-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-75-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-hydroxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-76-9 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 223607-77-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-78-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-80-5 CAPLUS


CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 223607-82-7 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-83-8 CAPLUS


CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-84-9 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(hexyloxy)- (9CI) (CA INDEX NAME)



RN 223607-86-1 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-87-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(hexyloxy)-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-88-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223607-89-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
 .alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-90-7 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-91-8 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223607-92-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-93-0 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-94-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223607-95-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223607-96-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223607-97-4 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223607-99-6 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-methyl-.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-00-2 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-methyl-.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223608-01-3 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 223608-02-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-03-5 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 223608-04-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy- (9CI) (CA INDEX NAME)



RN 223608-05-7 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-06-8 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-).




RN 223608-07-9 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 223608-08-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, 4-nitrophenyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 223608-09-1 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, 4-nitrophenyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 223608-18-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-ethoxy-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-19-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)ethoxy]-
.alpha.-ethoxy-, sodium salt (9CI) (CA INDEX NAME)



RN 223608-20-6 CAPLUS


CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-.alpha.-methyl-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-21-7 CAPLUS

CN Benzenepropanoic acid, .alpha.-[[4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-.alpha.-ethoxy-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● Na

RN 223608-22-8 CAPLUS
 CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-ethoxy-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-24-0 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-
.alpha.-(phenylmethoxy)-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-25-1 CAPLUS

CN Benzenepropanoic acid, .alpha.-butoxy-4-[2-(2,3-dihydro-4H-1,4-benzoxazin-
4-yl)ethoxy]-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-26-2 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-(hexyloxy)-, sodium salt (9CI) (CA INDEX NAME)




RN 223608-27-3 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-phenoxy-, sodium salt (9CI) (CA INDEX NAME)



RN 223608-28-4 CAPLUS

CN Benzenepropanoic acid, 4-[2-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethoxy]-.alpha.-methyl-.alpha.-phenoxy-, sodium salt (9CI) (CA INDEX NAME)



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:24:39 ON 21 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:24:44 ON 21 SEP 2003

L1 STRUCTURE UPLOADED

L2 11 S L1 SSS SAM

L3 171 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 15:26:16 ON 21 SEP 2003

L4 5 S L3

FILE 'CAOLD' ENTERED AT 15:26:56 ON 21 SEP 2003

=> s 13

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.40

172.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.26

STN INTERNATIONAL LOGOFF AT 15:27:06 ON 21 SEP 2003